Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$11.02 -1.3%	$12.39	$7.80 ▼ $28.09	$600.71M	N/A	580,767 shs	984,077 shs
DNLI Denali Therapeutics	$14.22 -1.4%	$13.83	$10.57 ▼ $33.33	$2.07B	1.49	1.13 million shs	1.75 million shs
HRMY Harmony Biosciences	$35.00 -0.5%	$31.67	$26.47 ▼ $41.61	$2.01B	0.87	612,734 shs	401,040 shs
KNSA Kiniksa Pharmaceuticals	$29.51 +2.2%	$23.96	$17.38 ▼ $29.75	$2.15B	0.06	499,912 shs	947,423 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	+1.36%	+17.97%	-20.29%	-29.14%	+1,115,999,900.00%
DNLI Denali Therapeutics	+3.52%	+10.58%	-9.82%	-11.37%	-30.24%
HRMY Harmony Biosciences	-0.42%	+4.27%	+17.36%	+4.30%	+18.34%
KNSA Kiniksa Pharmaceuticals	-0.79%	+5.94%	+3.96%	+35.78%	+49.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	1.6082 of 5 stars	3.5	0.0	0.0	1.2	0.8	0.6
DNLI Denali Therapeutics	4.3546 of 5 stars	4.5	1.0	4.7	2.9	2.5	0.0
HRMY Harmony Biosciences	4.9454 of 5 stars	4.6	4.0	0.0	3.5	3.3	4.4
KNSA Kiniksa Pharmaceuticals	2.9816 of 5 stars	3.5	2.0	0.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	189.23% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	137.06% Upside
HRMY Harmony Biosciences	3.11	Buy	$53.00	51.43% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	31.50% Upside

Current Analyst Ratings Breakdown

Latest BCAX, KNSA, HRMY, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	$330.53M	6.25	N/A	N/A	$7.42 per share	1.92
HRMY Harmony Biosciences	$744.85M	2.70	$2.62 per share	13.38	$7.97 per share	4.39
KNSA Kiniksa Pharmaceuticals	$481.17M	4.47	N/A	N/A	$6.23 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.59	11.25	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	118.02	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)

Latest BCAX, KNSA, HRMY, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	9.98	9.98
HRMY Harmony Biosciences	0.28	3.24	3.20
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
DNLI Denali Therapeutics	92.92%
HRMY Harmony Biosciences	86.23%
KNSA Kiniksa Pharmaceuticals	53.95%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
DNLI Denali Therapeutics	12.50%
HRMY Harmony Biosciences	23.60%
KNSA Kiniksa Pharmaceuticals	54.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable

BCAX, KNSA, HRMY, and DNLI Headlines

Recent News About These Companies

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

June 5 at 7:00 AM | globenewswire.com

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High - Here's What Happened

June 4 at 3:33 PM | marketbeat.com

Hennion & Walsh Asset Management Inc. Has $4.09 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

June 4 at 6:13 AM | marketbeat.com

26,808 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Bought by Squarepoint Ops LLC

June 4 at 3:54 AM | marketbeat.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Ameriprise Financial Inc.

June 2 at 3:15 AM | marketbeat.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 4,837 Shares

May 30, 2025 | marketbeat.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells $521,752.17 in Stock

May 30, 2025 | marketbeat.com

Sanj K. Patel Sells 62,116 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

May 30, 2025 | marketbeat.com

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 4.2% - Time to Buy?

May 30, 2025 | marketbeat.com

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 4,837 Shares

May 29, 2025 | insidertrades.com

Jefferies Financial Group Inc. Raises Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 29, 2025 | marketbeat.com

Voloridge Investment Management LLC Trims Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 29, 2025 | marketbeat.com

Woodline Partners LP Reduces Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 29, 2025 | marketbeat.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lifted by Nuveen Asset Management LLC

May 27, 2025 | marketbeat.com

State of Wyoming Takes $293,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 25, 2025 | marketbeat.com

Millennium Management LLC Purchases 263,146 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 25, 2025 | marketbeat.com

Deutsche Bank AG Buys 62,083 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 24, 2025 | marketbeat.com

Northern Trust Corp Raises Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 23, 2025 | marketbeat.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $316,920.00 in Stock

May 22, 2025 | insidertrades.com

Balyasny Asset Management L.P. Purchases New Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX, KNSA, HRMY, and DNLI Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$11.02 -0.15 (-1.30%)

Closing price 03:59 PM Eastern

Extended Trading

$11.02 +0.01 (+0.09%)

As of 04:04 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$14.22 -0.20 (-1.37%)

Closing price 03:59 PM Eastern

Extended Trading

$14.22 +0.00 (+0.02%)

As of 04:09 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$35.00 -0.16 (-0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$35.01 +0.01 (+0.02%)

As of 04:04 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$29.51 +0.63 (+2.17%)

Closing price 03:59 PM Eastern

Extended Trading

$29.52 +0.01 (+0.05%)

As of 04:04 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time